Associate Professor, Urology, University of Texas Southwestern Medical Center, Southwestern Medical School
Urology
Dr. Yair Lotan, MD
|
|
Give Review
Yair Lotan, MD is an expert in the field of Urology. He graduated from University of Texas Southwestern Medical School. He has 1 awards "CMS Meaningful Use Stage 1 Certification". Yair Lotan is also a published doctor. He has 100 publication published. The most recent publication is: Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomy. He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Prognostic Role of Cell Cycle and Proliferative Markers in Clear Cell Renal Cell Carcinoma.
- Current Status of Urinary Biomarkers for Detection and Surveillance of Bladder Cancer.
- The Utility of Chest X-Rays for T1a Renal Cell Carcinoma Surveillance.
- Cost Comparisons Between Different Techniques of Percutaneous Renal Biopsy for Small Renal Masses.
- Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes.
- Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies.
- Use of an electronic medical record to assess patient-reported morbidity after ureteroscopy.
- Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: A multi-institutional study.
- Final Pathologic Stage after Neoadjuvant Chemotherapy and Radical Cystectomy For Bladder Cancer: Does pT0 Predict Better Survival Than pTa/Tis/T1?
- Assessment of Prospectively Assigned Likert Scores for Targeted MR Imaging-Transrectal US Fusion Biopsies in Patients with Suspected Prostate Cancer.
- Association of distance to treatment facility on quality and survival outcomes after radical cystectomy for Bladder cancer.
- Lynch Syndrome: A Primer for Urologists and Panel Recommendations.
- Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward.
- Histologic upgrading in patients eligible for active surveillance on saturation biopsy.
- Feasibility of obtaining biomarker profiles from endoscopic biopsy specimens in upper tract urothelial carcinoma: Preliminary results.
- Projecting Benefits and Harms of Novel Cancer Screening Biomarkers: A Study of PCA3 and Prostate Cancer.
- Role of fibroblast growth factor in squamous cell carcinoma of the Bladder: Prognostic biomarker and potential therapeutic target.
- Evaluation of the prognostic significance of altered Mammalian target of rapamycin pathway biomarkers in upper tract urothelial carcinoma.
- Spectrum of diverse genomic alterations define non-clear cell Renal carcinoma subtypes.
- Can Urinary PCA3 Supplement PSA in the Early Detection of Prostate Cancer?
- Multi-Institutional Validation of the Predictive Value of KI-67 in Patients with High-Grade Urothelial Carcinoma of the Upper Urinary Tract.
- Multicenter evaluation of the role of UroVysion FISH assay in surveillance of patients with Bladder cancer: does FISH positivity anticipate recurrence?
- Perioperative outcomes and hospital reimbursement by type of radical Prostatectomy: results from a privately insured patient population.
- Validation of mammalian target of rapamycin biomarker panel in patients with clear cell Renal cell carcinoma.
- Potential cost-effectiveness of therapeutic drug monitoring in patients with resistant hypertension.
- Utility of Biomarkers in the Prediction of Oncological Outcome after Radical Cystectomy for Squamous Cell Carcinoma.
- Predictors of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic body radiation therapy for prostate Cancer.
- Use of the National Health and Nutrition Examination Survey to Calculate the Impact of Obesity and Diabetes on Cost and Prevalence of Urolithiasis in 2030.
- Clinical nodal staging scores for prostate Cancer: a proposal for preoperative risk assessment.
- Degree of Hydronephrosis predicts adverse pathological features and worse oncologic outcomes in patients with high-grade urothelial carcinoma of the upper urinary tract.
- Bladder cancer risk: Use of the PLCO and NLST to identify a suitable screening cohort.
- Prospective External Validation of Model for Bladder Cancer Detection.
- Association of perioperative Blood transfusion with oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma.
- Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate Cancer.
- Aspirin improves outcome in high risk prostate Cancer patients treated with radiation therapy.
- Medical management strategies to prevent recurrent nephrolithiasis are stagnant and stronger evidence is needed to reduce morbidity.
- Effect of ABO blood type on mortality in patients with urothelial carcinoma of the Bladder treated with radical cystectomy.
- Costs of radical prostatectomy for prostate Cancer: a systematic review.
- Squamous cell carcinogenesis and squamous cell carcinoma of the urinary Bladder: A contemporary review with focus on nonbilharzial squamous cell carcinoma.
- Combining smoking information and molecular markers improves prognostication in patients with urothelial carcinoma of the Bladder.
- The Economics of Bladder Cancer: Costs and Considerations of Caring for This Disease.
- Female Gender Is Associated With a Worse Survival After Radical Cystectomy for Urothelial Carcinoma of the Bladder: A Competing Risk Analysis.
- Impact of distal ureter management on oncologic outcomes following radical nephroureterectomy for upper tract urothelial carcinoma.
- Surgical management of the distal ureter during radical nephroureterectomy is an independent predictor of oncological outcomes: Results of a current series and a revie...
- Would the benefits of hexaminolevulinate fluorescence cystoscopy be eliminated if every patient received postoperative installation of intravesical chemotherapy?
- Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive Bladder cancer.
- Blood- and tissue-based biomarkers for prediction of outcomes in urothelial carcinoma of the Bladder.
- Bladder cancer in 2013: From genomics to imaging-advances along the care continuum.
- Gender-Specific Differences in Clinicopathologic Outcomes Following Radical Cystectomy: An International Multi-institutional Study of More Than 8000 Patients.
- Impact of ABO blood type on outcomes of patients with primary non-muscle-invasive Bladder cancer.
- Insulin-like Growth Factor Messenger RNA-binding Protein 3 Expression Helps Prognostication in Patients with Upper Tract Urothelial Carcinoma.
- Dysregulation of beta-catenin is an independent predictor of oncological outcomes in patients with clear cell Renal cell carcinoma.
- Extranodal Extension Is a Powerful Prognostic Factor in Bladder Cancer Patients with Lymph Node Metastasis.
- Summary of the 6th annual Bladder cancer think tank: New directions in urologic research.
- Female gender is associated with higher risk of disease recurrence in patients with primary T1 high-grade urothelial carcinoma of the Bladder.
- Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma.
- Conditional Survival After Radical Cystectomy for Bladder Cancer: Evidence for a Patient Changing Risk Profile over Time.
- Urine markers for detection and surveillance of Bladder cancer.
- Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the Bladder.
- Impact of statin use on biochemical recurrence in patients treated with radical Prostatectomy.
- Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate Cancer.
- Does increasing the nodal yield improve outcomes in contemporary patients without nodal metastasis undergoing radical Prostatectomy?
- Impact of smoking and smoking cessation on outcomes in Bladder cancer patients treated with radical cystectomy.
- Prediction of Intravesical Recurrence After Radical Nephroureterectomy: Development of a Clinical Decision-making Tool.
- Prospective comparison of molecular signatures in urothelial cancer of the Bladder and the upper urinary tract: is there evidence for discordant biology?
- The Challenge of Bacillus Calmette-Guérin Failure in Nonmuscle Invasive Bladder Cancer-What is the Next Step in Management?
- Diabetes mellitus without metformin intake is associated with worse oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma.
- Impact of Perioperative Blood Transfusion on the Outcome of Patients undergoing Radical Cystectomy for Urothelial Carcinoma of the Bladder.
- BAP1 immunohistochemistry in a multi-institutional cohort predicts outcomes in patients with clear cell Renal cell carcinoma.
- Comprehensive handbook for developing a Bladder cancer cystectomy database.
- Long-term Cancer-specific Outcomes of TaG1 Urothelial Carcinoma of the Bladder.
- A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate Cancer.
- Impact of smoking status and cumulative exposure on intravesical recurrence of upper tract urothelial carcinoma after radical nephroureterectomy.
- Multi-institutional validation of the ability of preoperative Hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma.
- Effect of statin use on outcomes of non-muscle-invasive Bladder cancer.
- Ki-67 is an independent predictor of oncological outcomes in patients with high-grade upper tract urothelial carcinoma: results of a prospective analysis and a review ...
- Urothelial carcinoma at the uretero-enteric Junction: multi-center evaluation of oncologic outcomes after radical nephroureterectomy.
- Pathologic Nodal Staging Scores in Patients Treated with Radical Prostatectomy: A Postoperative Decision Tool.
- Prospective evaluation of a preoperative biomarker panel for prediction of upstaging at radical cystectomy.
- Prognostic Role of Cell Cycle and Proliferative Biomarkers in Patients with Clear Cell Renal Cell Carcinoma.
- Ki67 is an independent predictor of oncological outcomes in patients with localized clear-cell Renal cell carcinoma.
- Prediction of Cancer specific survival after radical nephroureterectomy for upper tract urothelial carcinoma: development of an optimized postoperative nomogram using ...
- Impact of fluid intake in the prevention of urinary system Diseases: a brief review.
- Assessing treatment response after induction Bacillus Calmette-Guerin for carcinoma in situ of the urinary Bladder: can post-induction random Bladder biopsies be avoided?
- Urinary cytology for the detection of urothelial carcinoma of the Bladder--a flawed adjunct to cystoscopy?
- Cost-Effectiveness of Fluorescence In Situ Hybridization in Patients with Atypical Cytology for the Detection of Urothelial Carcinoma.
- Prospective Evaluation of a Molecular Marker Panel for Prediction of Recurrence and Cancer-specific Survival After Radical Cystectomy.
- Cost Effectiveness Of Risk-Stratified Follow-Up After Urethral Reconstruction: A Decision Analysis.
- Impact of smoking and smoking cessation on oncologic outcomes in primary non-muscle-invasive Bladder cancer.
- Evaluation of anatomic and morphologic nomogram to predict malignant and high-grade disease in a cohort of patients with small Renal masses.
- Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the Bladder treated with radical cystectomy.
- Predictors of survival in patients with soft tissue surgical margin involvement at radical cystectomy.
- Re: Radiotherapy With or Without Chemotherapy in Muscle-invasive Bladder Cancer.
- Impact of Renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy.
- Predictors of Cancer-specific mortality after disease recurrence following radical cystectomy.
- Comparative Analysis of Oncologic Outcomes of Partial Ureterectomy vs Radical Nephroureterectomy in Upper Tract Urothelial Carcinoma.
- Gender-Specific effect of smoking on upper tract urothelial carcinoma outcomes.
- Lymphovascular invasion in clear cell renal cell carcinoma-Association with disease-free and Cancer-specific survival.
- Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical Prostatectomy.
Schools
Baylor University
University Tx Swstn Med Center
Procedures Preformed
- Cystectomy
- Cystometry
- Cystourethroscopy and Transurethral Resection of Bladder Neck
- Excision of Testicular Lesion
- View All
Conditions Treated
- Atrophic Vaginitis
- Bladder Cancer
- Bladder Infection
- Bladder Stones
- View All
Doctors Specialties
- Urology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Texas Southwestern Medical School -
Baylor College of Medicine
Hospital
-
University of Texas Southwestern Medical Center -
Veterans Affairs North Texas Health Care System
Drug Facts
| NPI NUMBER | 1407815541 | |
| NPPES Provider LastName | LOTAN | |
| NPPES Provider FirstName | YAIR | |
| NPPES Provider ZIPCode | 753907208 | |
| NPPES Provider State | TX | |
| Specialty Description | Urology | |
| Total Claim Count | 946.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 36.0 | |
| Percent Opioid Claims | 3.81 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1407815541 |
| Last Name Of The Provider | LOTAN |
| First Name Of The Provider | YAIR |
| View All |
Similar Doctors
|
|
Dr. Allen F. Morey, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Michael B. Gruber, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Myron G. Fine, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ginger B. Isom-Batz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jennifer M. Wimberly, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nakizito N. Kazigo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sujeet S. Acharya, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeffrey C. Gahan, MD |
|
|
Dr. Stephen P. Faddegon, MD |
|
|
Dr. Shawn Mathur, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Timothy J. Tausch, MD |
|
|
Dr. Micah A. Jacobs, MD
This Doctor is OpenDoctor Recommended.
|